New combo therapy targets Hard-to-Treat tumors
NCT ID NCT03444714
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RiMO-301 (a drug injected directly into the tumor)
- What this could lead to
- If it works, this could point toward a new way to treat advanced tumors by combining a targeted drug with radiation.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not effectiveness. It may not lead to a proven treatment, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?